It is no secret that there is a digital transformation happening across life sciences and healthcare. This seismic shift is being facilitated by cutting-edge technology that is enabling the interrogation and aggregation of the vast quantities of data that we now have at our fingertips. The adoption of automated processes using technologies like artificial intelligence (AI), which incorporates human intelligence into machines through a set of rules, and machine learning (ML), an application of AI whereby the computer learns automatically through its experiences, is key to collecting and analyzing the vast and varied data that is now available and facilitating a move to a personalized approach to medicine.

A new realm of possibility

While the term has been used more frequently in recent years, personalized medicine is not a new concept; healthcare professionals have been tailoring treatment to an individual’s specific needs since the advent of medicine. However, the ground-breaking advancements being made today allow us to understand a patient’s potential susceptibility to certain diseases, and their predicted response to treatments.

Facilitating this shift is the availability of ‘big data’, characterized by the three Vs:

  • Velocity – the speed at which data is being collected
  • Volume – the amount of data collected
  • Variety – the broad range of data types being collected, for example imaging or unstructured data

It is clear that routine patient data fulfils each of these categories, with neuroimaging, for example, producing more than 10 petabytes of data each year, with a nine-fold increase in data complexity over the last three decades. [1] Pharmaceutical researchers working with biomarkers and genome sequencing have also made rapid developments in recent years. In fact, genomic data are expected to reach exponential dimensions by the next decade, which would exceed other big data areas such as astronomy. [1]

In addition to more standard data types, such as images or phenotypic data from patients’ individual electronic health records (EHR), we are now also able to access patient-generated health data from wearable and implantable devices. Currently, a lot of this information is collected for specific purposes, such as for an oncology patient’s treatment plan, but we are starting to see the use of real-time sensors to collect continuous biometrics data too. One of the main consequences of this shift is the ability to analyze data on health, treatment, and lifestyle as one combined data set.

The ways in which we can collect data are becoming more varied and sophisticated, however, collecting the data is just the first hurdle. Rigorous processing and analysis is needed so the data stands up to the levels of scrutiny surrounding drug development and healthcare.

Understanding analytics

As more data of more types is gleaned from more sources, it all needs to come together to allow for real-time processing and cleaning during the time a study is conducted. There is an urgent need for the life sciences research industry to better understand data science and focus on the expert application of the deep knowledge we can glean from modern statistical techniques.

These techniques are already being used effectively in genomics and signal processing of images, which are in the discovery phase. However, we will see even more value using them to refine treatments in the ‘real world’, in signal detection for safety surveillance, to identify subgroups of patients who may get increased benefit from a treatment, or who are at most risk of side effects.

Adopting a new approach

The use of big data analytics and AI will become more mainstream in the months and years to come, and we will see it being used across the clinical research pipeline. This will enable a greater collaboration between public health and clinical research, which is currently divided. It is important to note, however, that we still need active experimentation to discern cause and effect, to identify the primary factors and noise variables, to separate efficacy versus effectiveness, and to demonstrate scientific rigour. Any systems adopted must be able to allow this much-needed collaboration while still enabling the ongoing requirements of successful trials.

Platforms that can take in real-world data and support data science and AI analysis with full data provenance for regulatory submission are vital to the success of our industry’s digital transformation. Much of the foundation is already in place, now it is time for us to grasp the opportunity with both hands.

Visit to find out how we can help you make the leap to better, future-proof clinical trials.

[1] Cirillo, D., Valencia, A., Big data analytics for personalized medicine (6 April 2019) Current Opinion in Biotechnology

Latest articles

Digital transformation can happen for any sponsor: How small and mid-sized biopharmaceutical companies can easily achieve digital innovation for their clinical data

In just a couple of decades, information technology has undergone a radical transformation –a sweeping evolution from floppy drives to data warehouses to data lakes. Our industry has unfortunately not ridden the arc of technology at the pace of other…

Read article

A better way to drive your digital transformation

As the ways in which clinical trials are conducted and monitored continue to modernize at pace, there is an urgent need for digital transformation in the industry. If sponsors are to realize their goals of running flexible, decentralized trials (DCT),…

Read article

Five predictions for the future of decentralized clinical trials

The message was clear from industry leaders last year – today’s clinical trials need decentralized solutions. More complexity means intensive data capture and continuous flows are essential, and vital strategic decisions rely on real-time data analysis and intelligence. Existing point…

Read article